Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease

Anticancer Research

Volumn 27, Issue 6 A, 2007, Pages 3749-3756

  Mitsuyama, Keiichi ^a   Matsumoto, Satoshi ^b   Masuda, Junya ^a   Yamasaki, Hiroshi ^a   Kuwaki, Kotaro ^a   Takedatsu, Hidetoshi ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Crohn's disease; gp130; IL 6; IL 6 receptor; Review; STAT3; Ulcerative colitis

Indexed keywords

ATLIZUMAB; CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN;

COLORECTAL CANCER; CONFERENCE PAPER; ENTERITIS; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CYTOKINE RECEPTOR GP130; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 35348951458     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. Bamias G, Nyce MR, De La Rue SA and Cominelli F: New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 143: 895-904, 2005.
2. Podolsky DK and Fiocchi C: Cytokines, chemokines, growth factors, eicosanoids, and other bioactive molecules in inflammatory bowel disease. In: Inflammatory Bowel Disease. Kirsner JB (ed.). Philadelphia, W.B. Saunders Company, pp. 191-207, 2000.
3. Sartor RB: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407, 2006.
4. Hirano T, Akira S, Taga T and Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 11: 443-449, 1990.
5. Kishimoto T: The biology of interleukin-6. Blood 74: 1-10, 1989.
6. Kishimoto T: Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21, 2005.
7. Mitsuyama K, Sata M and Rose-John S: Interleukin-6 transsignaling in inflammatory bowel disease. Cytokine Growth Factor Rev 17: 451-461, 2006.
8. Rose-John S: Coordination of interleukin-6 biology by membrane bound and soluble receptors. Adv Exp Med Biol 495: 145-151, 2001.
9. Taga T and Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819, 1997.
10. Rose-John S, Scheller J, Elson G and Jones SA: Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80: 227-236, 2006.
11. Scheller J, Ohnesorge N and Rose-John S: Interleukin-6 transsignalling in chronic inflammation and cancer. Scand J Immunol 63: 321-329, 2006.
12. Scheller J and Rose-John S: Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (Berl) 195: 173-183, 2006.
13. Mackiewicz A, Schooltink H, Heinrich PC and Rose-John S: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149: 2021-2027, 1992.
14. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T and Kishimoto T: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58: 573-581, 1989.
15. Jones SA, Richards PJ, Scheller J and Rose-John S: IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 25: 241-253, 2005.
16. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, Brem G, Meyer zum Buschenfelde KH and Rose-John S: The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183: 1399-1406, 1996.
17. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T and Kishimoto T: Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82: 1120-1126, 1993.
18. Mahida YR, Kurlac L, Gallagher A and Hawkey CJ: High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 32: 1531-1534, 1991.
19. Gross V, Andus T, Caesar I, Roth M and Scholmerich J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 102: 514-519, 1992.
20. Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhor T, Bakos S, Vogelsang H, Gangl A and Lochs H: Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 94: 2156-2164, 1999.
21. Van Kemseke C, Belaiche J and Louis E: Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis 15: 206-210, 2000.
22. Mitsuyama K, Sata M and Tanikawa K: Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn 26: 20-28, 1991.
23. Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, Arima N, Oriishi T, Harada K, Fujisaki K, Sata M and Tanikawa K: Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 50: 104-111, 1991.
24. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA and Strom TB: Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 37: 818-826, 1992.
25. Suzuki Y, Saito H, Kasanuki J, Kishimoto T, Tamura Y and Yoshida S: Significant increase of interleukin 6 production in blood mononuclear leukocytes obtained from patients with active inflammatory bowel disease. Life Sci 47: 2193-2197, 1990.
26. Andus T, Gross V, Casar I, Krumm D, Hosp J, David M and Scholmerich J: Activation of monocytes during inflammatory bowel disease. Pathobiology 59: 166-170, 1991.
27. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP and Raedler A: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94: 174-181, 1993.
28. Jones SC, Trejdosiewicz LK, Banks RE, Howdle PD, Axon AT, Dixon MF and Whicher JT: Expression of interleukin-6 by intestinal enterocytes. J Clin Pathol 46: 1097-1100, 1993.
29. Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, Ina K, Kanayama K, Ando T, Matsuura T, Yamaguchi T, Morise K, Ieda M, Iokawa H, Ishihara A and Sarai S: Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 40: 949-959, 1995.
30. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M and Yoshimura A: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193: 471-481, 2001.
31. Yamamoto M, Yoshizaki K, Kishimoto T and Ito H: IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164: 4878-4882, 2000.
32. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, Tripodi M, Musiani P and Poli V: Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 26: 45-56, 2004.
33. Mudter J, Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle PR, Lehr HA, Schmidt J and Neurath MF: Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 100: 64-72, 2005.
34. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A and Odum N: Constitutive STAT3 activation in intestinal T-cells from patients with Crohn's disease. J Biol Chem 278: 16777-16781, 2003.
35. Yoshimura A, Mori H, Ohishi M, Aki D and Hanada T: Negative regulation of cytokine signaling influences inflammation. Curr Opin Immunol 15: 704-708, 2003.
36. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I and Akira S: Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49, 1999.
37. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S and Neurath MF: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 6: 583-588, 2000.
38. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF and Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268: 160-167, 2001.
39. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ and Fuller GM: C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 189: 599-604, 1999.
40. Vollmer P, Walev I, Rose-John S and Bhakdi S: Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun 64: 3646-3651, 1996.
41. Mitsuyama K, Toyonaga A Sasaki E, Ishida O, Ikeda H, Tsuruta O, Harada K, Tateishi H, Nishiyama T and Tanikawa K: Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36: 45-49, 1995.
42. Hosokawa T, Kusugami K, Ina K, Ando T, Shinoda M, Imada A, Ohsuga M, Sakai T, Matsuura T, Ito K and Kaneshiro K: Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 14: 987-996, 1999.
43. Kallen KJ, Galle PR and Rose-John S: New developments in IL-6 dependent biology and therapy: where do we stand and what are the options? Expert Opin Investig Drugs 8: 1327-1349, 1999.
44. Kallen KJ: The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 1592: 323-343, 2002.
45. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M and Kishimoto T: Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95: 8222-8226, 1998.
46. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V and Ciliberto G: Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187: 461-468, 1998.
47. Mihara M, Takagi N, Takeda Y and Ohsugi Y: IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 112: 397-402, 1998.
48. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS and Jones SA: Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 171: 3202-3209, 2003.
49. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T and Panayi GS: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46: 3143-3150, 2002.
50. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T and Kishimoto T: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989-996, 2004.
51. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K and Nishimoto N: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48: 1521-1529, 2003.
52. Wendling D, Racadot E and Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20: 259-262, 1993.
53. Yoshizaki K, Nishimoto N, Mihara M and Kishimoto T: Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20: 247-259, 1998.
54. Mitsuyama K, Tomiyasu N, Suzuki A Takaki K, Takedatsu H, Masuda J, Yamasaki H, Matsumoto S, Tsuruta O, Toyonaga A and Sata M: A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol 143: 125-131, 2006.
55. Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Deviere J and Franchimont D: Profile of soluble cytokine receptors in Crohn's disease. Gut 54: 488-495, 2005.
56. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, Handa K, Tsuruta O, Funabashi H, Scheller J, Toyonaga A and Sata M: STAT3 activation via interleukin-6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55: 1263-1269, 2006.
57. Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2): 1-5, 2003.
58. Lightdale CJ and Sherlock P: Neoplasia and gastrointestinal malignancy in inflammatory bowel disease. In: Inflammatory Bowel Disease. Kirsner JB and Shorter RG (eds.). Philadelphia, Lea & Febiger, pp. 281-298, 1988.
59. Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen KJ and Rose-John S: Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278: 38829-38839, 2003.
60. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S and Neurath MF: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501, 2004.
61. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S and Neurath MF: IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4: 217-220, 2005.
62. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN and Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135, 1995.
63. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF and Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029-1035, 1997.
64. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A and Curman B: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805-1811, 2005.
65. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID and Forbes A: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52: 998-1002, 2003.
66. Chang JT and Lichtenstein GR: Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 3: 220-228, 2006.